Welcome to our dedicated page for Nasus Pharma SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma Ltd. reports that on September 30, 2025 it closed a partial exercise of the over-allotment option from its recently completed initial public offering. Underwriters purchased an additional 3,824 ordinary shares at the IPO price of $8.00 per share. The company received net proceeds of approximately $28 thousand from this option exercise, after underwriting discounts. Including this amount, total net proceeds from the IPO are approximately $8.8 million after underwriting discounts and estimated offering expenses. Nasus plans to use these funds primarily to advance development of its intranasal epinephrine program, including manufacturing scale-up and additional Phase 2 studies, with the remainder for general corporate purposes such as working capital and capital expenditures.
Nasus Pharma Ltd. reported governance changes approved by its Board of Directors. The Board appointed Chief Executive Officer Dan Teleman to also serve as a director, filling a vacancy in accordance with the company’s Amended and Restated Articles of Association.
Teleman will serve as a Class III director, with his term scheduled to expire at the annual general meeting of shareholders to be held in 2028. The Board also changed the composition of its Compensation Committee, replacing David Silberman with Ronnie Hershman as a committee member.
Capital Point Ltd. reported ownership of 575,129 ordinary shares of Nasus Pharma Ltd., representing 6.35% of the outstanding class based on 9,059,635 shares. The filing shows Capital Point has sole voting and dispositive power over those shares and indicates the holdings were not acquired to change or influence control of the issuer. The report identifies the filer as an Israel-organized entity and provides principal office addresses for both the issuer and filer. The statement is a Schedule 13G disclosure of beneficial ownership and does not include transactions, financial results, or forward-looking commentary.